Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fox Corp Class A (FOXA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FOXA trades at $54.12, up 0.71% today, with a bearish technical signal despite recent earnings beats. The company reported strong 2025 results with revenue of $16.3B and net income of $2.26B, but faces headwinds from its $22B Roku acquisition. Analyst consensus remains positive with a $67.80 price target, though technical indicators show selling pressure near resistance at $55.

The outlook balances solid fundamentals against acquisition integration risks. FOXA's attractive valuation (P/E 14.24) and cash flow strength support upside potential, but investor sentiment is cautious due to leverage from the Roku deal. Near-term performance hinges on successful execution of streaming strategy amid industry consolidation.